Jazz Pharmaceuticals (NASDAQ: JAZZ) received a number of ratings updates from brokerages and research firms in the last week:

  • Jazz Pharmaceuticals is now covered by analysts at Guggenheim. They set a “buy” rating and a $60.00 price target on the stock.
  • Jazz Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Barclays Capital.
  • Jazz Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Leerink Swann.
  • Jazz Pharmaceuticals is now covered by analysts at Brean Murray. They set a “buy” rating and a $81.00 price target on the stock.
  • Jazz Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Oppenheimer.

Jazz Pharmaceuticals, Inc. traded down 0.26% on Friday, hitting $56.999. Jazz Pharmaceuticals, Inc. has a 52-week low of $34.02 and a 52-week high of $58.94. The company has a market cap of $3.279 billion and a price-to-earnings ratio of 24.49.

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.